Aurinia Pharmaceuticals Inc. (AUPH) stock

AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3062% below fair value

$15.73−0.48 (-2.96%)

Close on Nov 13, 2026Market cap $2.11BP/E 6.9Yield –

Aurinia Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Aurinia Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Aurinia Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AUPH.

Revenue growth21.0% · median 38.4%

Gross margin90.6% · median 90.2%

Operating margin48.6% · median 6.9%

Net margin97.7% · median -1.8%

Advertisement
300 × 250

See a number that looks wrong?